Drug Development Targeting the Glycogen Synthase Kinase-3β (GSK-3β)-Mediated Signal Transduction Pathway : Role of GSK-3β in Adult Brain

スポンサーリンク

概要

• 論文の詳細を見る

• Glycogen synthase kinase-3β (GSK-3β) is a constitutively active kinase. Since its activation results in neurofibrillary tangle (NFT) deposits in aged and Alzheimer’s disease (AD) brains, GSK-3β may be inhibited under normal conditions but activated under pathological conditions. Given its link to NFT formation, we sought to determine whether GSK-3β exists in the brain as a “pathological time bomb” that promotes disease development. To address this hypothesis, we analyzed GSK-3β heterozygote (GSK+/−) mice, which express GSK-3β at 50% wild-type levels. When tested in the Morris water maze test, GSK+/− mice surprisingly exhibited retrograde amnesia. Further analysis indicated that GSK+/− mice had impaired memory reconsolidation but normal memory consolidation. Therefore, we concluded that GSK-3β activation is required for memory reconsolidation in the adult brain.

• 社団法人 日本薬理学会の論文
• 2009-02-20

著者

• Takashima Akihiko

  Laboratory For Alzheimer's Disease Riken Brain Science Institute

関連論文

• Involvement of apoptosis and cholinergic dysfunction in Alzheimer's disease
• Discussions on phosphorylated tau and other biochemical markers
• Familial Alzheimer's disease-associated mutations block translocation of full-length presenilin 1 to the nuclear envelope
• Decreased Aβ secretion by cells expressing familial Alzheimer's disease-linked mutant presenilin 1
• Drug Development Targeting the Glycogen Synthase Kinase-3β (GSK-3β)-Mediated Signal Transduction Pathway : Role of GSK-3β in Adult Brain

スポンサーリンク